Conversely, post-diagnosis vaginal estrogen therapy has been tentatively associated with a lower risk of BC recurrence52, specific mortality53, or all-cause mortality54, although safety concerns have been raised in patients currently treated with aromatase inhibitors54. The gene discussed is CYP19A1; the disease is breast cancer.